```html

Xerophthalmia (Due to Sjögren’s Syndrome): A Comprehensive Medical Guide

Overview

Xerophthalmia is the medical term for severe dryness of the ocular surface. When it occurs as a manifestation of Sjögren’s syndrome—a chronic autoimmune disease that primarily attacks the body’s moisture‑producing glands—it is sometimes called **Sjogren‑related keratoconjunctivitis sicca**. The condition results from inadequate tear production, leading to an unstable tear film, irritation, and, if untreated, damage to the cornea and conjunctiva.

Who it affects

• Women are disproportionately affected, accounting for <≈90% of cases of primary Sjögren’s syndrome.
• Typical age of onset is between 40 and 60 years, but the disease can appear at any age.
• Although less common, men and children can develop Sjögren’s‑related xerophthalmia.

Prevalence

• Overall Sjögren’s syndrome prevalence is estimated at **0.1‑0.6 %** of the general population (≈1‑6 per 1,000 people) [1].
• Up to **80 %** of patients with Sjögren’s report dry eye symptoms at some point in their disease course [2].
• In rheumatology clinics, dry eye is the most frequent ocular manifestation, with a prevalence of **≈70‑90 %** among diagnosed patients [3].

Symptoms

Dry eye can range from mild irritation to severe ocular surface disease. Common and less‑common symptoms include:

• Burning or gritty sensation: The eye feels as though sand or a foreign body is present.
• Persistent dryness: A feeling that the eyes cannot stay lubricated, even after using artificial tears.
• Redness (hyperemia): Irritation can cause dilated superficial blood vessels.
• Blurry vision, especially after reading or computer use: An unstable tear film distorts the corneal surface.
• Photophobia: Light sensitivity due to corneal epithelial irregularities.
• Excessive tearing (reflex tearing): Paradoxically, severe dryness can trigger reflex lacrimation.
• Eye fatigue: Often worsens after prolonged visual tasks.
• Stringy mucus discharge: Accumulation of mucin from the conjunctiva.
• Contact lens intolerance: Inability to wear lenses comfortably.
• Corneal epithelial breakdown: Visible spots, erosions, or ulcerations that can cause pain.
• Recurrent conjunctivitis or blepharitis: Inflammation of eyelid margins.
• Reduced tear meniscus height: Clinically measured decrease in the thin wedge of tear fluid at the lower lid.

Causes and Risk Factors

Pathophysiology

Sjögren’s syndrome is an autoimmune disorder in which the body’s immune system mistakenly attacks exocrine glands, especially the lacrimal (tear) and salivary glands. Lymphocytic infiltration leads to glandular atrophy, fibrosis, and impaired secretory function. The resulting hyposecretion of aqueous tear fluid creates a hyper‑osmolar tear film that triggers inflammation of the ocular surface, perpetuating a cycle of damage.

Risk Factors

• Gender: Female sex (≈9:1 ratio).
• Age: Peak incidence 40‑60 years.
• Genetics: HLA‑DR and HLA‑DQ alleles increase susceptibility.
• Other autoimmune diseases: Rheumatoid arthritis, systemic lupus erythematosus, thyroiditis.
• Environmental triggers: Viral infections (e.g., Epstein‑Barr), smoking, and certain medications (antihistamines, antidepressants) can exacerbate dryness.
• Family history: First‑degree relatives with Sjögren’s or other autoimmune conditions.

Diagnosis

Accurate diagnosis involves both confirming Sjögren’s syndrome and assessing ocular surface health.

Step 1: Confirm Sjögren’s Syndrome

• Medical history & physical exam: Dry mouth, parotid gland enlargement, arthralgias, and systemic features.
• Serologic testing: Anti‑SSA/Ro and anti‑SSB/La antibodies (present in 60‑70 % of patients). Positive rheumatoid factor (RF) and antinuclear antibodies (ANA) are also common.
• Objective gland testing: Schirmer I test (filter paper placed under the lower eyelid for 5 minutes; ≤5 mm wetting suggests severe dry eye) and sialometry for salivary flow.
• Minor salivary gland biopsy: Focal lymphocytic sialadenitis is the gold‑standard histologic finding.

Step 2: Evaluate Ocular Surface

• Schirmer I test (without anesthesia): Measures basal + reflex tear production.
• Tear Break‑Up Time (TBUT): Fluorescein dye is applied; time until first dry spot appears (<10 seconds is abnormal).
• Ocular Surface Disease Index (OSDI) questionnaire: Patient‑reported symptom severity.
• Corneal staining with fluorescein or lissamine green: Visualizes epithelial defects; graded by the Oxford or NEI scale.
• Meibomian gland evaluation: Assess for associated evaporative dry eye.
• Imaging (e.g., OCT of the cornea): Detects subtle epithelial thinning.

Treatment Options

Management is multimodal—aimed at restoring tear film stability, reducing inflammation, and protecting the ocular surface.

1. Artificial Tears & Lubricants

• Preservative‑free drops: Use 4–6 times daily; important for patients with compromised epithelium.
• Gel or ointment formulations: Provide longer residence time; ideal for nighttime use.
• Hydrogel “smart” drops (e.g., Systane Ultra): Contain propylene glycol for enhanced spreading.

2. Anti‑Inflammatory Medications

• Topical cyclosporine A 0.05 % (Restasis) or 0.1 % (Cequa): Improves tear production by inhibiting T‑cell activation; effects appear after 3–6 months.
• Topical lifitegrast 5 % (Xiidra): Blocks LFA‑1/ICAM‑1 interaction, reducing ocular surface inflammation.
• Short course of topical corticosteroids: Reserved for acute flares or severe epithelial breakdown; taper to avoid cataract or glaucoma.

3. Punctal & Canalicular Occlusion

Insertion of silicone plugs (temporary) or permanent cautery reduces tear drainage, preserving existing tears. Success rates of symptom improvement range from 60‑80 % [4].

4. Systemic Therapies (for underlying Sjögren’s)

• Hydroxychloroquine: Disease‑modifying antirheumatic drug (DMARD) that may improve systemic and ocular symptoms.
• Biologics (e.g., rituximab): Anti‑CD20 monoclonal antibody; limited evidence for dry eye but benefits systemic disease.
• Secretagogues (e.g., pilocarpine, cevimeline): Stimulate exocrine gland secretion; can modestly increase tear volume.

5. Procedural Interventions

• Thermal pulsation (LipiFlow): Treats meibomian gland dysfunction that frequently co‑exists with Sjögren’s.
• Intense pulsed light (IPL): Reduces ocular surface inflammation and improves meibum quality.
• Amniotic membrane graft or autologous serum eye drops: For severe epithelial defects, these provide growth factors and anti‑inflammatory cytokines.

6. Lifestyle & Environmental Modifications

• Humidifier use (30‑40 % relative humidity).
• Avoid direct airflow (fans, air conditioners).
• Protect eyes from wind and dust with wrap‑around sunglasses.
• Limit screen time; follow the 20‑20‑20 rule (every 20 min, look at something 20 ft away for 20 seconds).
• Stay hydrated; drink 2–3 L of water daily.

Living with Xerophthalmia (due to Sjögren’s syndrome)

Adopting daily habits can dramatically improve comfort and preserve vision.

• Establish a tear‑replacement schedule: Keep a drop bottle at each workstation and bedside.
• Warm compresses: Apply a moist, warm (not hot) cloth to closed eyelids for 5 minutes, 2‑3 times daily to improve meibomian gland secretion.
• Eyelid hygiene: Use diluted baby shampoo or commercial lid scrubs to reduce bacterial load.
• Nutrition: Omega‑3 fatty acids (EPA/DHA) 1–2 g daily have been shown to improve tear film stability.
• Regular ophthalmic follow‑up: At least once every 6–12 months, or sooner if symptoms worsen.
• Medication adherence: Keep a weekly chart to track eye drops and systemic meds.
• Eye protection during activities: Goggles while swimming or during dusty chores.

Prevention

Because xerophthalmia in Sjögren’s results from an autoimmune process, primary prevention is limited. However, the following measures can reduce severity and delay onset:

• Early diagnosis of Sjögren’s syndrome and prompt systemic treatment.
• Avoidance of known tear‑drying medications when possible (e.g., antihistamines, isotretinoin).
• Smoking cessation – tobacco worsens ocular surface inflammation.
• Protective eyewear in windy or low‑humidity environments.
• Regular eye‑exam screening for patients with rheumatoid arthritis, lupus, or other connective‑tissue diseases.

Complications

If left untreated, chronic xerophthalmia can lead to serious ocular morbidity:

• Corneal epithelial breakdown & ulceration: May progress to stromal melting and perforation.
• Infectious keratitis: Staphylococcus, Pseudomonas, or fungal organisms can invade compromised epithelium.
• Conjunctival scarring (symblepharon): Adhesion of eyelid to eyeball, limiting ocular mobility.
• Visual acuity loss: Persistent surface irregularities cause fluctuating or decreased vision.
• Contact lens intolerance: Limits a common visual aid.
• Psychosocial impact: Chronic discomfort can affect quality of life and lead to anxiety or depression.

When to Seek Emergency Care

References

1. Mayo Clinic. “Sjogren’s syndrome.” Updated 2023. https://www.mayoclinic.org.
2. CDC. “Sjogren’s Syndrome.” 2022. https://www.cdc.gov.
3. Cleveland Clinic. “Dry Eye (Keratoconjunctivitis Sicca).” 2024. https://my.clevelandclinic.org.
4. Jones L, et al. “Efficacy of punctal plugs in Sjögren’s‑related dry eye.” *Ophthalmology*. 2021;128(4):e58‑e66. DOI:10.1016/j.ophtha.2020.11.012.
5. American Academy of Ophthalmology. “Dry Eye Syndrome Preferred Practice Pattern.” 2022. https://www.aao.org.

```